🔍 Observations
Topline
- Revenue from operations grew 16.8% YoY (₹232,415 Mn → ₹271,484 Mn), led by Pharma (₹205,415 Mn → ₹224,121 Mn, +9.1%) and a near-doubling of Consumer Products (₹26,976 Mn → ₹39,540 Mn, +46.6%).
- Medical Technologies contributed ₹7,823 Mn in FY26 vs ₹24 Mn in FY25 — full-year impact of an acquired business.
- Q4FY26 revenue of ₹75,870 Mn was up 16.2% YoY vs Q4FY25 (₹65,279 Mn), with sequential improvement from Q3FY26 (₹68,645 Mn).
Bottomline
- Net profit grew 11.3% YoY (₹45,255 Mn → ₹50,400 Mn); exceptional items of ₹5,166 Mn (vs ₹2,196 Mn in FY25) weighed on reported PAT.
- Pre-exceptional PBT rose 14.3% YoY (₹62,463 Mn → ₹71,377 Mn) — underlying earnings quality remains strong.
- Effective tax rate dropped meaningfully: 23.4% in FY26 vs 23.4% in FY25 — stable, no distortion from deferred tax movements at the net level.
Margins
- EBITDA proxy (PBT before exceptional + D&A + Finance costs): ₹71,377 + ₹14,080 + ₹4,389 = ₹89,846 Mn on revenue of ₹271,484 Mn → EBITDA margin ~33.1% vs ₹62,463 + ₹9,158 + ₹1,699 = ₹73,320 Mn on ₹232,415 Mn → 31.5% in FY25. ~160 bps expansion YoY.
- Net profit margin: ₹50,400 / ₹271,484 = 18.6% vs ₹45,255 / ₹232,415 = 19.5% — 90 bps compression, driven by higher D&A (₹14,080 Mn vs ₹9,158 Mn) and finance costs (₹4,389 Mn vs ₹1,699 Mn) post-acquisitions.
- Consumer Products EBIT margin compressed sharply: ₹2,671 / ₹39,540 = 6.8% vs ₹3,470 / ₹26,976 = 12.9% — the acquired business is dilutive at EBIT level.
Growth Trajectory
- 3-year revenue compounding is intact; FY26’s 16.8% growth is above-industry for a company of this scale.
- Pharma segment — the core engine — delivered only 9.1% growth; incremental revenue acceleration depended heavily on acquisitions.
- Medical Technologies segment is loss-making (EBIT: -₹1,782 Mn) and rapidly scaling costs — trajectory unclear without further disclosure.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- EBITDA margin expanded ~160 bps YoY to ~33.1% — operating leverage visible in core Pharma even as new businesses scale up.
- Pre-exceptional PBT CAGR remains healthy; FX tailwind of ₹12,805 Mn in FY26 (vs ₹1,634 Mn gain in FY25) boosted reported operating profit significantly.
- Consumer Products nearly doubled revenue to ₹39,540 Mn — signals successful integration and rapid scale-up of acquired entity.
- EPS grew 11.4% (₹44.97 → ₹50.09) despite significantly higher D&A and finance cost load from inorganic activity — underlying earnings power is durable.
- Equity base is strong: Total equity of ₹295,822 Mn with equity attributable to shareholders of ₹271,114 Mn — low dilution risk.
- Pharma EBIT margin: ₹70,488 / ₹224,121 = 31.5% vs ₹59,231 / ₹205,415 = 28.8% — 270 bps expansion in the highest-quality segment.
🔴 Red Flags
- Operating cash flow collapsed: ₹21,166 Mn in FY26 vs ₹67,811 Mn in FY25 — working capital absorbed ₹26,237 Mn (vs a release of ₹15,359 Mn in FY25), and FX adjustments removed ₹17,533 Mn from operating profit adjustments.
- Debt surged: Total borrowings rose from ₹31,695 Mn to ₹117,695 Mn (current ₹85,815 Mn + non-current ₹31,880 Mn) — largely acquisition-funded, but leverage profile has changed materially.
- Trade receivables jumped 32.6% (₹40,848 Mn → ₹54,157 Mn) against 16.8% revenue growth — receivables days deteriorating; collection efficiency risk.
- Consumer Products EBIT halved despite revenue doubling — integration costs or structural margin dilution from acquired business requires monitoring.
- Medical Technologies burning cash: EBIT loss of ₹1,782 Mn on ₹7,823 Mn revenue — no visible path to profitability disclosed.
- Exceptional items rising: ₹5,166 Mn in FY26 vs ₹2,196 Mn in FY25 — recurring “one-time” charges reduce earnings quality credibility.
- Capex + acquisitions totalled ₹92,733 Mn (₹26,715 Mn capex + ₹7,225 Mn asset acquisition + ₹58,793 Mn business acquisition) — free cash flow is deeply negative; sustainability depends on acquired assets performing.
📊 Balance Sheet Analysis
- Asset base expanded 40.9% (₹372,017 Mn → ₹524,066 Mn) — driven by goodwill (₹52,421 Mn → ₹75,427 Mn) and intangibles (₹18,496 Mn → ₹73,324 Mn); intangible-heavy balance sheet warrants scrutiny on amortisation and impairment risk.
- Net debt position: Cash + current investments = ₹8,552 Mn + ₹57,758 Mn = ₹66,310 Mn vs total borrowings of ₹117,695 Mn → net debt of ~₹51,385 Mn. From net cash to net debt in one year — a structural shift.
- Current ratio: Current assets ₹199,061 Mn / Current liabilities ₹157,119 Mn = 1.27x — adequate but thinned vs prior year (₹170,461 Mn / ₹90,416 Mn = 1.89x).
- Equity coverage remains solid at 56.4% of total assets — balance sheet is not distressed, but the leverage trajectory must stabilise.
💰 Cash Flow Analysis
- OCF-to-PAT conversion deteriorated sharply: ₹21,166 Mn OCF vs ₹50,400 Mn PAT = 42% conversion ratio (FY25: ₹67,811 Mn / ₹45,255 Mn = 150%) — working capital build and FX adjustments are the primary culprits.
- Investing outflow of ₹82,961 Mn was almost entirely acquisition-driven (₹58,793 Mn for businesses + ₹7,225 Mn for assets) — organic capex of ₹26,715 Mn alone represents 53% of OCF.
- Financing inflows of ₹58,069 Mn funded the acquisition gap — ₹70,710 Mn in new non-current borrowings raised, partly offset by ₹9,679 Mn repayments; dividend payout jumped to ₹11,063 Mn (vs ₹3,025 Mn in FY25).
- Free cash flow (OCF minus capex): ₹21,166 Mn − ₹26,715 Mn = −₹5,549 Mn — first negative FCF year; not alarming if acquisitions integrate well, but leaves no margin for error.
💡 Investment Outlook
Zydus enters FY27 as a structurally larger business, with EBITDA margins expanding and Pharma EBIT at a multi-year high — the core engine is performing well.
However, a single-year acquisition spree has inverted the balance sheet from net cash to net debt, collapsed OCF conversion, and introduced two loss-making or margin-dilutive segments (Med Tech, Consumer Products) that will define the re-rating story.
The margin inflection thesis hinges on Consumer Products recovering toward historical EBIT margins and Medical Technologies reaching breakeven — neither is visible in FY26 numbers.
Monitor FY27 OCF recovery and debt reduction cadence closely before ascribing acquisition premium to valuations.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial data, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.